What does it take to redefine psychiatric care with psychedelic therapies? In this episode, Dr. Dan Karlin of MindMed joins host Dr. Talar Hopyan to discuss the clinical, regulatory and cultural shifts underway in mental health.

They explore the momentum behind MindMed’s LSD program for anxiety and depression, how the team is preparing for NDA filing and commercialization and why purposeful growth—not hype—is key to long-term success in psychedelics.

What you’ll learn:

• Why MindMed’s MM120 program could reshape the treatment landscape for anxiety
• How collaboration with regulators is enabling more responsible innovation
• What intentional scaling means for the future of psychedelic biotech

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.